 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Select Publications
Albain K et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, node-positive, ER-positive breast cancer (S8814,INT0100). San Antonio Breast Cancer Symposium 2007;Abstract 10.
Albain K et al. Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, node-positive, estrogen (ER) and/or progesterone (PgR) receptor positive breast cancer: Mature outcomes and new biologic correlates on Phase III Intergroup trial 0100 (SWOG-8814). San Antonio Breast Cancer Symposium 2004;No abstract available.
Harris L et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25(33):5287-312. Abstract
Paik S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24(23):3726-34. Abstract
Paik S et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351(27):2817-26. Abstract
Van de Vijver MJ et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347(25):1999-2009. Abstract
Van ‘t Veer LJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415(6871):530-6. Abstract
 |
 |
TOPICS
Challenges in HER2 Testing and Interpretation
- Select publications
Assessment of Estrogen Receptor Status
- Select publications
Evolving Role of Genomic Assays in Breast Cancer
- Select publications
Tissue Biomarkers in the Management of Breast Cancer:
A CME Audio Series and Activity
 |
 |
 |
 |
 |
